About SAGE Therapeutics
SAGE Therapeutics is a company based in Boston (United States) founded in 1971 by Vincent Foglia was acquired by Supernus Pharmaceuticals in June 2025. SAGE Therapeutics has raised $105.8 million across 6 funding rounds from investors including Bank of America, Supernus Pharmaceuticals and Orbimed. The company has 487 employees as of February 29, 2024. SAGE Therapeutics operates in a competitive market with competitors including Boston Scientific, Medtronic, Jazz Pharmaceuticals, GE Healthcare and Johnson & Johnson, among others.
- Headquarter Boston, United States
- Employees 487 as on 29 Feb, 2024
- Founders Vincent Foglia
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$105.8 M (USD)
in 6 rounds
-
Latest Funding Round
$649.99 M (USD), Post-IPO
Jan 15, 2021
-
Investors
Bank of America
& 6 more
-
Employee Count
487
as on Feb 29, 2024
-
Acquired by
Supernus Pharmaceuticals
(Jun 16, 2025)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of SAGE Therapeutics
Unlock access to complete
Leadership Team
35 people
Data Analysis and Operations Team
10 people
Software Development Team
8 people
Legal and Compliance
6 people
Human Resources and Administration
6 people
Operations Team
5 people
Senior Team
4 people
Product Management Team
3 people
Unlock access to complete
Funding Insights of SAGE Therapeutics
SAGE Therapeutics has successfully raised a total of $105.8M across 6 strategic funding rounds. The most recent funding activity was a Post-IPO round of $649.99 million completed in January 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in SAGE Therapeutics
SAGE Therapeutics has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include Bank of America, Supernus Pharmaceuticals and Orbimed.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Locked | Locked | Locked | |
|
Multi-stage investment firm invests in healthcare and life sciences companies
|
Locked | Locked | Locked | |
|
Venture capital funding is provided to early-stage life science companies.
|
Locked | Locked | Locked |
Investor details for SAGE Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by SAGE Therapeutics
Investment portfolio details for SAGE Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - SAGE Therapeutics
Detailed financials for SAGE Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Sage Therapeutics Comparisons
Peer comparison for SAGE Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of SAGE Therapeutics
SAGE Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Boston Scientific, Medtronic, Jazz Pharmaceuticals, GE Healthcare and Johnson & Johnson, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Wide range of medical devices
|
|
| Locked | Locked | Locked |
Medical equipment for treating over 30 chronic diseases is developed.
|
|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Materials management solutions are provided for healthcare organizations.
|
|
| Locked | Locked | Locked |
Healthcare solutions are provided by Johnson & Johnson globally.
|
|
| Locked | Locked | Locked |
Diagnostic and surgical products for women's healthcare are provided.
|
Detailed competitors of SAGE Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Sage Therapeutics
Complete news archive for SAGE Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about SAGE Therapeutics
SAGE Therapeutics was founded in 1971 and raised its 1st funding round 40 years after it was founded.
SAGE Therapeutics is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Vincent Foglia is the current CEO of SAGE Therapeutics. They have also founded this company.
SAGE Therapeutics is a funded company, having raised a total of $105.8M across 6 funding rounds to date.
As of Feb 29, 2024, the latest employee count at SAGE Therapeutics is 487.
SAGE Therapeutics was founded in 1971 in Boston, United States, and focuses on the biotechnology sector. Drug candidates targeting GABAA and NMDA receptors are developed for rare central nervous system disorders, including those related to mood, seizure, cognition, anxiety, sleep, pain, epilepsy, and movement. A pipeline of products is maintained, with the lead candidate SAGE-547 intended for postpartum depression treatment. Operations emphasize therapeutic innovation in neurology.
SAGE Therapeutics's top competitors include Jazz Pharmaceuticals, GE Healthcare and Medtronic.
SAGE Therapeutics has 7 investors. Key investors include Bank of America, Supernus Pharmaceuticals, Orbimed, Arch Venture Partners, and Foresite Capital.